topicHyaluronic Acid Skin Aging Randomized Trial
claimIn accordance with EMA Committee for Advanced Therapies (EMA-CAT) recommendations (Guideline on Human Cell-Based Medicinal Products, 2015, section 2.2.4a), this approach qualifies as a “technique, since the processing does not alter the biological characteristics, physiological functions, or structural properties of the cells.
evidence level2
citationGentile Pietro (2026)
sourceAutologous fibroblast therapy for facial rejuvenation: A randomized open-label controlled study
topicHyaluronic Acid Skin Aging Randomized Trial
claim20 patients with mild to moderate dermal thinning, reduced elasticity, and wrinkles were assigned to the study group (SG) and treated with Am-FBs (A–C).
evidence level2
citationGentile Pietro (2026)
sourceAutologous fibroblast therapy for facial rejuvenation: A randomized open-label controlled study
topicHyaluronic Acid Skin Aging Randomized Trial
claimThe Risk Evaluation and Mitigation Strategies (REMSs) incorporating Elements to Assure Safe Use (ETASU) were applied in Am-FBs and HA-based skin booster treatments, significantly reducing safety-related risks.
evidence level2
citationGentile Pietro (2026)
sourceAutologous fibroblast therapy for facial rejuvenation: A randomized open-label controlled study
topicHyaluronic Acid Skin Aging Randomized Trial
claim, , , The natural aging process leads to the degradation of the dermal extracellular matrix (ECM), decreased fibroblast activity, and a loss of skin elasticity.Traditional cosmetic procedures, such as hyaluronic acid (HA)-based skin boosters, provide temporary benefits, but autologous cell-based therapies offer a biologically driven regenerative approach.
evidence level2
citationGentile Pietro (2026)
sourceAutologous fibroblast therapy for facial rejuvenation: A randomized open-label controlled study